Dublin, Oct. 04, 2021 (GLOBE NEWSWIRE) -- The "Cell Based Assay & High Content Screening Markets" report has been added to ResearchAndMarkets.com's offering.
Cell-Based Assays are a mainstay of drug development and scientific research, but growth is now accelerating as the race for a COVID-19 cure gains speed.
On top of this, new technology is allowing Cell-Based Assays to be used to measure any aspect of cell function. This market just keeps on growing with no end in sight. The workhorse of the pharmaceutical industry is becoming a central player in biotechnology.
This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.
The technology is moving faster than the market. Genomics and Immunology are playing a role too. Find the opportunities and pitfalls. Understand growth expectations and the ultimate potential market size.
Players in a Dynamic Market
Academic Research Lab
Contract Research Organization
Genomic Instrumentation Supplier
Cell Line and Reagent Supplier
Factors Driving Growth
The Insurance Effect
Factors Limiting Growth
CBA Development Challenges
Signalling and Reporter Genes
The Next Five Years
Cell Based Assays Recent Developments
Axxam and FUJIFILM Cellular Dynamics Announce Strategic Alliance
Cancer Genetics to Acquire Organoid Startup Stemonix
Curi Bio Acquires Artificial Intelligence Firm Dana Solutions
CRISPR Screens Uncover Novel Cancer Therapy Targets
ERS Genomics Licenses CRISPR-Cas9 Patents to Axxam
New Transcriptomics Assay Facilitates Compound Screens
Carta Biosciences Betting on Gene Interaction Mapping
High-throughput Identifies cancer drug candidates
Velabs Therapeutics partners with Alytas Therapeutics to develop a novel immune-based therapy for obesity
InSphero platform selected to test Cyclerion's sGC stimulator technology
OcellO to provide in vitro research services to Merus
Charles River Laboratories to acquire Citoxlab
Reaction Biology Corporation Purchases ProQinase GmbH
Cisbio extends its assay portfolio for immuno-oncology drug discovery
STEMCELL Technologies Launches Next-Generation Culture System
Abcam Acquires Calico Biolabs
Evotec announces achievement in Celgene alliance utilizing IPSC screening
Fujifilm Cellular Dynamics Inc. launches iCELL Microglia
Cisbio and Excellerate Bioscience partner
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Profiles of Key Cell Based Assay Companies
Aurora Instruments Ltd
Beckman Coulter Diagnostics
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Cell Biolabs, Inc
Cell Signaling Technology, Inc.
Charles River Laboratories
Enzo Life Sciences, Inc
Eurofins DiscoverX Corporation
Fujifilm Cellular Dynamics International
Lonza Group Ltd.
Merck & Co., Inc
New England Biolabs, Inc
Stemcells Technologies Canada Inc
Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/7n5ac3
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900